Literature DB >> 16618345

Seronegative myasthenia gravis: comparison of neurophysiological picture in MuSK+ and MuSK- patients.

L Padua1, P Tonali, I Aprile, P Caliandro, E Bartoccioni, A Evoli.   

Abstract

The aim of this study was to compare the neurophysiological and clinical pictures of a large sample of seronegative myasthenia gravis (SNMG) patients with and without anti-MuSK antibodies. Fifty-two consecutive SNMG patients were retrospectively evaluated. They had undergone an extended neurophysiological evaluation: repetitive nerve stimulation (RNS), single fiber EMG (SFEMG), and electromyography (EMG) with nerve conduction study. A muscle biopsy was performed in 11 of 52 patients, the edrophonium test in 44 of 52 patients and anti-AChR antibodies and anti-MuSK antibodies were tested in all patients. Anti-MuSK antibodies were detected in 25 SNMG patients (48.1%). The number of women in the MuSK+ group was significantly higher (P = 0.01) than in the MuSK- group. Seronegative MuSK+ patients are more severely affected and the deficit often involves the bulbar and the respiratory muscles. No statistically significant differences were observed in the edrophonium test between MuSK+ and MuSK- groups. The RNS test was abnormal in a significantly higher number of MUSK- patients than MUSK+ patients (P < 0.00001). With regard to SFEMG data, MuSK- patients were characterized to have more severe neurophysiological pattern. Our observations showed several differences between the clinical and neurophysiological pictures of MUSK+ and MUSK- patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16618345     DOI: 10.1111/j.1468-1331.2006.01214.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  8 in total

1.  In response to "current approach to seronegative myasthenia" by Z. Argov.

Authors:  Michal Haran
Journal:  J Neurol       Date:  2010-11-18       Impact factor: 4.849

Review 2.  Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.

Authors:  Michael H Rivner; Mamatha Pasnoor; Mazen M Dimachkie; Richard J Barohn; Lin Mei
Journal:  Neurol Clin       Date:  2018-05       Impact factor: 3.806

Review 3.  Current approach to seronegative myasthenia.

Authors:  Zohar Argov
Journal:  J Neurol       Date:  2010-09-18       Impact factor: 4.849

Review 4.  Review: Male systemic lupus erythematosus: a review of sex disparities in this disease.

Authors:  L-J Lu; D J Wallace; M L Ishimori; R H Scofield; M H Weisman
Journal:  Lupus       Date:  2009-11-27       Impact factor: 2.911

Review 5.  Bedside and laboratory diagnostic testing in myasthenia.

Authors:  Katie Yoganathan; Alexander Stevenson; Awais Tahir; Ross Sadler; Aleksandar Radunovic; Naveed Malek
Journal:  J Neurol       Date:  2022-02-10       Impact factor: 6.682

6.  Differential serum interferon-β levels in autoimmune thyroid diseases.

Authors:  Chao-Wen Cheng; Kam-Tsun Tang; Wen-Fang Fang; Ting-I Lee; Jiunn-Diann Lin
Journal:  Arch Med Sci       Date:  2021-01-31       Impact factor: 3.707

7.  Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status.

Authors:  Shin Joong Oh
Journal:  J Clin Neurol       Date:  2009-06-30       Impact factor: 3.077

8.  Repetitive Nerve Stimulation in MuSK-Antibody-Positive Myasthenia Gravis.

Authors:  Seung Woo Kim; Mun Kyung Sunwoo; Seung Min Kim; Ha Young Shin; Il Nam Sunwoo
Journal:  J Clin Neurol       Date:  2017-05-15       Impact factor: 3.077

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.